Oxford - Recombinant Overlapping Peptide
Tumours can often avoid being targeted by these T Cells by looking like a cell found normally in the body often referred to as “self”. If a group of T Cells can be encouraged to recognise these tumours as foreign and not self then they will attack the tumour and provide an effective treatment against it. Injecting a preparation that stimulates these T Cells effectively vaccinates the patient against the tumour providing immediate treatment and longer term protections against it. The Oxford Vacmedix technology – the Recombinant Overlapping Peptides – is a powerful preparation that delivers just this result.
-
Most popular related searches
Products Details
The ROP technology platform has wide applications in cancer and infectious diseases. New ROP vaccines are easy to design and fast to synthesize.
Compared with conventional vaccines the ROP technology shows:
- much greater efficacy as it is applicable all HLA types and stimulates CD8 as well as CD4 T-cells
- a much greater immunogenic effect and
- the potential for synergy with other immune oncology agents, to enhance and extend the duration of effect.
The recombinant approach also has low manufacturing costs and simple regulatory pathways.
Customer reviews
No reviews were found for Oxford - Recombinant Overlapping Peptide. Be the first to review!